ACHILLION PHARMACEUTICALS, INC.

  • Good News for This Anti-Viral Giant

    By Mohsin Saeed - July 9, 2013 | Tickers: ACHN, GILD, IDIX

    The HCV (Hepatitis C) drug market is extremely lucrative. According to estimates, the HCV drug market will exceed $20 billion by 2020. Gilead (NASDAQ: GILD) is expected to lead the market with estimated sales of around $4 billion or 20% HCV market share. A number of companies working on their own HCV treatments threaten the market leadership of Gilead. These small biopharmaceutical companies are the wild cards is this industry more »

  • Why Investors Should Care About Hepatitis C

    By Nick Chiu - July 9, 2013 | Tickers: ABT, ABBV, ACHN, GILD

    Hepatitis C, caused by the hepatitis C virus (HCV), is an infectious disease affecting the liver. An estimated 130 million-200 million people worldwide are infected with hepatitis C, and more than 350,000 people die every year from hepatitis C-related liver diseases.

    Diagnosis

    HCV is the most common chronic blood-borne infection in the United States and the leading cause of liver transplants, according to the Centers for Disease Control and more »

  • Three Biotech Giants to Look For

    By Abir Karmakar - April 3, 2013 | Tickers: ACHN, BIOL, GALE

    In the world of biotech investing, there are many companies to choose from. When the market is on a riding stride, investment in more speculative stocks that have inflated valuations can get tough. There still may be potential for several biotech stocks that are immune to downturn or sidewise movements in the market. Galena Biopharma  (NASDAQ: GALE), Biolase (NASDAQ: BIOL), and Achillion Pharmaceuticals (NASDAQ: ACHN) are the three stocks that more »

  • Hepatitis C In Play for 2013?

    By Terry Chrisomalis - February 25, 2013 | Tickers: ACHN, BMY, IDIX, VRTX

    In the world of biotech stocks a lot of companies are starting to incorporate Hepatitis C treatments into their pipelines. Hepatitis C is starting to garner a lot of attention, and these biotech companies are not wrong to be chasing this target disease. Why, you ask? Because there are currently 170 million people worldwide infected with Hep C, and this could mean huge opportunity for biotech companies that are in more »

  • Disappointing Fourth Quarter - Reason to Sell?

    By Jordo Bivona - February 10, 2013 | Tickers: ACHN, GILD, PFE, VRTX

    Vertex Pharmaceuticals (NASDAQ: VRTX) saw sales of its hepatitis C drug, Incivek, drop sharply in the fourth quarter, year-on-year. This article will address the company's latest earnings release and its future prospects. The company attributes the decrease to patients with hepatitis C opting for alternative treatments through other available medicines. Incivek was approved by the FDA only in May 2011 and the decline emphasizes the cutthroat competitive business environment more »

  • Life Sciences: Upcoming Events for Week of January 13

    By John Macris - January 14, 2013 | Tickers: ACHN, ANAC, PATH

    The life sciences industry arguably represents the most unique investment opportunity among the universe of publicly-traded companies. Stock research analysts have dedicated entire books to the subject of life sciences, and there are both positive and negative reasons why this sector redefines the traditional rules of investing. In my opinion, however, the most distinctive characteristic of life sciences is that individual stock price movement is more correlated with the underlying more »

  • The Most Important New Drug of 2012

    By Jordo Bivona - January 9, 2013 | Tickers: ACHN, GILD, IDIX, VRTX

    Forbes recently crowned Vertex Pharmaceuticals' (NASDAQ: VRTX) Kalydeco the most important new drug of 2012. Forbes said that Kalydeco, used to treat cystic fibrosis, is a triumph of genetics and drug development and the first treatment to directly address the genetic defect that causes the disease.

    Kalydeco will only help 4 percent of the 70,000 people who suffer from declining lung function, a damaged pancreas, and shortened lives due more »

  • Will Kalydeco Push Vertex Higher?

    By Jordo Bivona - December 13, 2012 | Tickers: ACHN, GILD, VRTX

    Vertex Pharmaceuticals (NASDAQ: VRTX) announced that Health Canada has approved Kalydeco (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Cystic fibrosis is a rare genetic disease for which there is no cure and is caused by a defective or missing more »

  • Invest in the Great Progress of Hepatitis C

    By Streetwise Reports - December 8, 2012 | Tickers: ACHN, GILD, IDIX, JNJ

    By George S. Mack of The Life Sciences Report.

    For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

    There are a lot of drug candidates in company pipelines for hepatitis C (HCV). In fact, your head could spin as you recite the product code number and letter combinations. I spoke with Sagient Research Analyst John Tucker who had just gotten back more »

  • Which Hedge Fund is Animating Achillion?

    By Meena Krishnamsetty - September 10, 2012 | Tickers: ACHN, BMY, GILD

    QVT Financial, a hedge fund managed by Daniel Gold, specializes in healthcare-related stocks, holding about half of its equity portfolio in biotech and pharmaceutical stocks. According to its 13F filing, as of the end of June 2012, the fund's top holdings included VIVUS (VVUS), Medivation (MDVN), and TPC Group (TPCG), all of which have had break-out years, returning 80 percent of more (view Gold's portfolio here).

    Most recently more »

  • Biotech Stocks Live (and Die) on the Calendar

    By Streetwise Reports - August 15, 2012 | Tickers: ACHN, ARNA, GILD, OREX, VVUS

    By George S. Mack, The Life Sciences Report

    For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

     

    Since the beginning of the biotech revolution, analysts have kept spreadsheets, tables and calendars to catch the next whiff of data coming out of companies whose futures hang in the balance. I recently interviewed Vice President Michael Hay of Sagient Research Systems for The more »

  • Former Drug Developer Discovers Next-Generation Biotech Stocks

    By Streetwise Reports - June 22, 2012 | Tickers: ACHN, ACOR, AMRN, IDIX, MDVN

    Former Drug Developer Discovers Next-Generation Biotech Stocks

    By George S. Mack, The Life Sciences Report

    Management is the key ingredient

    Raghuram "Ram" Selvaraju, an analyst I recently interviewed for The Life Sciences Report, began his initial career in translational drug discovery at Serono in 2000 with early and remarkable success. As a young researcher he demonstrated real insight and ability when he discovered the first novel protein candidate ever developed more »

  • Achillion: A Compelling 'Buy' Candidate Now

    By Maxwell Fisher - April 16, 2012 | Tickers: ACHN, DNDN, HGSI

    There are numerous biotech stocks out there and the key to smart investing is finding one that is a good value. This might not be the cheapest available and it might not be the overall best, but it will be a solid earner for the money you invest. What I always tell investors searching for a good value is to find mid-price companies with strong pipelines. In general, avoid companies more »

  • Achillion Gets FDA Fast Track for Hep C Drug

    By Brandy Betz - January 5, 2012 | Tickers: ACHN, INHX, MRK, VRTX

    Achillion Pharmaceuticals (NASDAQ: ACHN) received FDA fast track approval yesterday for ACH-1625, a protease inhibiting hepatitis C treatment currently in Phase 2 of clinical trials. The drug is notable for its once daily dosage recommendation and improvement of side effects and tolerability compared to medications currently in the market. Hepatitis C is a potentially chronic inflammation of the liver that can cause cirrhosis, which in turn can lead to liver more »